Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,005 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Adult Subjects Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Avocado and Postprandial Responses

NCT06818032
View directory record Official record
Conditions
Healthy, Healthy Volunteer, Healthy Volunteers, Healthy Adult, Healthy Male and Female Subjects, Healthy Subjects, Healthy Volunteers Only, Healthy Non-smokers
Interventions
Negative control, Avocado, Fat and fiber addition
Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

NCT05642546
View directory record Official record
Conditions
Healthy
Interventions
NM8074, Placebo
Drug
Lead sponsor
NovelMed Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Mass Balance Absorption and AME of VBR

NCT04637139
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Vebicorvir (VBR)
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

NCT01756495
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod, Moxifloxacin, Losmapimod matched Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Liposomal Glutathione Supplementation in Healthy Subjects

NCT02278822
View directory record Official record
Conditions
Healthy
Interventions
Low dose oral liposomal glutathione supplementation, High dose oral liposomal glutathione supplementation
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

NCT05731544
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
443 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
36
States / cities
Canoga Park, California • Fountain Valley, California • La Mesa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

NCT01563328
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, BCV, TVR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions

NCT00990301
View directory record Official record
Conditions
Healthy
Interventions
Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc., Uniretic® 15mg/25mg Tablets
Drug
Lead sponsor
Paddock Laboratories, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.

NCT00481182
View directory record Official record
Conditions
Healthy Subjects
Interventions
fosamprenavir + ritonavir + methadone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2009 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects

NCT01232413
View directory record Official record
Conditions
Healthy Subjects, Cardiac Repolarization
Interventions
Placebo, ASP1941, Moxifloxacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543268
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects

NCT06802185
View directory record Official record
Conditions
Pain
Interventions
ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product)
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 4, 2026, 10:08 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04565717
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, NASH
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

NCT02207790
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 4, 2026, 10:08 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

NCT01273103
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
200mg [14C]- GSK2248761
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
30 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of SB 659032 on Platelet Function

NCT01750827
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB659032
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01436422
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants

NCT07136103
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-277, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

NCT04482569
View directory record Official record
Conditions
Bacterial Infections
Interventions
XNW4107
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bosutinib In Subjects With Renal Impairment

NCT01233882
View directory record Official record
Conditions
Renal Disease, End-Stage, Renal Insufficiency, Chronic, Renal Insufficiency, Acute
Interventions
Bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
5
States / cities
DeLand, Florida • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 4, 2026, 10:08 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-951 in Healthy Adults

NCT06610279
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-951, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

NCT04091061
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
PF-06865571 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Celecoxib Bioavailability in Healthy Subjects

NCT00296127
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Celecoxib
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 4, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects

NCT01493869
View directory record Official record
Conditions
Healthy, Hepatic Impairment
Interventions
cabozantinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 4, 2026, 10:08 AM EDT